Clinical trials: Arterial Hypotension
Apheresis Related Hypotension
IMPACT (Improving Plasma Collection) Clinical Trial
Prospective, multi-center, randomized, controlled clinical trial to study the safety and effectiveness of a novel plasma collection system software.
- Trial name
- IMPACT (NCT04320823)
- Testing
- Updated Plasma Collection Feature, Current Plasma Collection Approach
- Where
- 3 sites in United States
- Volunteers
- 3,443 people, healthy volunteers welcome
- Sponsor
- Haemonetics Corporation
Acute Hypotension
Assessment of the Implementation of the ResQGARD® Impedance Threshold Device by the San Antonio Fire Department
This study is attached to a comprehensive quality assurance/quality improvement (QA/QI) program conducted by the Office of the medical director, and is designed to contribute to generalizable knowledge to determine effectiveness…
- Trial name
- NCT01780350
- Testing
- ResQGARD ITD
- Volunteers
- 200 people
- Sponsor
- Advanced Circulatory Systems
Orthostatic Hypotension, Reflex Syncope
Data Collection - Of Syncope Tilt Table Testing Study
To characterize the impact of orthostatic hypotension (OH) and reflex syncope on signals measured using a wearable cardiac monitor prototype device.
- Trial name
- COST3 (NCT03721393)
- Testing
- Wearable heart monitor
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Boston Scientific Corporation
Septic Shock, Sepsis
VBI-S for the Treatment of Hypotension in Hypovolemic Septic Shock Patients
This study is being conducted to evaluate the safety and effectiveness of VBI-S in elevating the blood pressure of septic shock patients with absolute or relative hypovolemia.
- Conditions
- Septic Shock, Sepsis, Hypovolemia
- Trial name
- NCT04257136
- Testing
- VBI-S
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- Vivacelle Bio
Neurogenic Orthostatic Hypotension, Non-Diabetic Autonomic Neuropathy
Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)
The purpose of this study is to assess the durability of effect of Droxidopa in treating symptoms of neurogenic orthostatic hypotension in patients with Primary Autonomic Failure (Pure Autonomic Failure, Multiple System Atrophy…
- Conditions
- Neurogenic Orthostatic Hypotension, Non-Diabetic Autonomic Neuropathy, Multiple System Atrophy, Dopamine Beta Hydroxylase Deficiency
- Trial name
- NOH303 (NCT00738062)
- Testing
- Droxidopa
- Where
- 54 sites in United States, Australia and 2 more
- Volunteers
- 103 people
- Sponsor
- Chelsea Therapeutics
Sepsis, Hypotension
Extended Therapy of Drotrecogin Alfa (Activated) 4 vs 7 Days Infusion
The purpose of this study is to determine whether continued administration of Drotrecogin Alfa (Activated) up to additional 72 hours - after the so far recommended 96 hour infusion period - results in a more rapid resolution of…
- Trial name
- NCT00190788
- Testing
- Drotrecogin Alfa (Activated)
- Where
- 2 sites in United States, France
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Catecholamine-resistant Hypotension (CRH), Distributive Shock
A Study of LJPC-501 in Paediatric Patients With Hypotension Associated With Distributive or Vasodilatory Shock
The objective of this study is to evaluate the effect of LJPC-501 infusion on mean arterial pressure (MAP) as assessed by standard of care vasopressor dose reduction in pediatric patients with catecholamine-resistant hypotension…
- Conditions
- Catecholamine-resistant Hypotension (CRH), Distributive Shock, High Output Shock, Septic Shock
- Trial name
- NCT03623529
- Testing
- LJPC-501 (angiotensin II)
- Where
- 2 sites in Belgium, Lithuania
- Volunteers
- 100 people
- Sponsor
- La Jolla Pharmaceutical Company
Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment.
- Trial name
- CYPRESS (NCT05696717)
- Testing
- Ampreloxetine
- Where
- 79 sites in United States, Argentina and 18 more
- Volunteers
- 102 people
- Sponsor
- Theravance Biopharma
Spinal Cord Injury, Orthostatic Hypotension
ARC Therapy to Restore Hemodynamic Stability and Trunk Control in People With Spinal Cord Injury
The goal of this interventional study is to evaluate the safety and preliminary effectiveness of the ARC-IM Therapy to improve hemodynamic management in people with sub-acute or chronic spinal cord injury.
- Trial name
- HemON-NL (NCT05941819)
- Testing
- ARC-IM Thoracic System implantation
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- ONWARD Medical, Inc.
Hypotension of Hemodialysis, Hypotension
Measuring Cardiovascular Stress in Patients on Hemodialysis Study II
The overall goal is to evaluate the predictive accuracy of a measure of autoregulatory adequacy derived from CVInsight and compare it with other measures in recognizing hypotensive events during hemodialysis..
- Conditions
- Hypotension of Hemodialysis, Hypotension, Estimated Dry Weight, Myocardial Injury
- Trial name
- NCT02182089
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Intelomed, Inc.
Hypertension, Hypotension
Accuracy of Non-Invasive Blood Pressure Measurement in Adults
The purpose of this study is to compare the accuracy of the Sotera ViSi, an investigational device, to auscultation (measurement with a cuff) in determining systolic and diastolic blood pressure (BP) in adult subjects.
- Trial name
- NIBP (NCT01183741)
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Sotera Wireless, Inc.
Parkinson Disease (PD), MSA - Multiple System Atrophy
Test-retest Trial With [11C]MODAG-005 in PD or MSA and AMHC - Pilot Phase
This is an open-label, single-center Phase 1 study evaluating the safety, tolerability, and test-retest characteristics of [11C]MODAG-005, an investigational positron emission tomography/computed tomography (PET/CT) radioligand…
- Conditions
- Parkinson Disease (PD), MSA - Multiple System Atrophy, Healthy Adult Participants
- Trial name
- PIOSA (NCT07640542)
- Testing
- [11C]MODAG-005
- Where
- Germany
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- MODAG GmbH
Apheresis Related Hypotension
Evaluation of the Aurora Xi New Nomogram Software 2.0
A clinical trial to evaluate the safety and effectiveness of the Aurora Xi Plasmapheresis System with a new plasma collection volume nomogram.
- Trial name
- NCT06122935
- Testing
- Aurora Xi New Nomogram Software 2.0, Aurora Xi Currently Approved Software 1.3
- Where
- 3 sites in United States
- Volunteers
- 6,735 people, healthy volunteers welcome
- Sponsor
- Fenwal, Inc.
Symptomatic Neurogenic Orthostatic Hypotension
Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
A Phase 3 study to evaluate efficacy, safety, and tolerability of ampreloxetine (TD-9855) in subjects with primary autonomic failures (MSA, PD, or PAF) and symptomatic nOH with up to 4 weeks of treatment.
- Trial name
- SEQUOIA (NCT03750552)
- Testing
- ampreloxetine
- Where
- 125 sites in United States, Australia and 17 more
- Volunteers
- 195 people
- Sponsor
- Theravance Biopharma
Chronic Heart Failure With Reduced Ejection Fraction
An Observational Study to Learn More About Vericiguat Treatment Patterns and Its Safety in People With Chronic Heart Failure With Reduced Ejection Fraction in Routine Medical Care in the United States
This is an observational study in which data already collected from people with chronic heart failure with reduced ejection fraction (HFrEF) are studied.
- Trial name
- HOVER (NCT06363110)
- Testing
- Vericiguat (Verquvo, BAY1021189)
- Where
- United States
- Volunteers
- 1,400 people
- Sponsor
- Bayer
Hypertension, Hypoxia
The VISION-Acute Study
AIM: We propose an innovative approach using Lifelight® smart technology that will enable the continued provision of high level patient care at the same time as reducing pressure on nursing and equipment resources.
- Conditions
- Hypertension, Hypoxia, Hypotension
- Trial name
- NCT04589923
- Testing
- Lifelight® Data Collect Blood Pressure Group, Lifelight® Data Collect Oxygen Saturation Group
- Where
- United Kingdom
- Volunteers
- 127 people
- Sponsor
- Xim Limited
Healthy Volunteers
A Trial to Learn if Different Doses of REGN7544 Are Safe in Healthy Adult Participants
The study is researching an experimental drug called REGN7544.The study is focused on healthy adults. The aim of the study is to see how safe and tolerable the study drug is in healthy adults.
- Trial name
- NCT05970718
- Testing
- REGN7544
- Where
- New Zealand
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Renal Dialysis
Prospective, Multicentre, Randomized, Controlled, Cross-over Study on the Safety and Performance of the Biologic Fusion Option of DialogiQ Compared to Haemodialysis Without Biologic Fusion in Hypotension Prone Patients on Maintenance Haemodialysis
The goal of this prospective, randomized, controlled, cross-over, multicentric study is to demonstrate the safety of bioLogic Fusion in patients on chronic haemodialysis or hemodiafiltration prone to hypotensive episodes.
- Trial name
- NCT06376968
- Testing
- BioLogic Fusion
- Where
- Italy
- Volunteers
- 56 people
- Sponsor
- B.Braun Avitum AG
Healthy, Hypertension
Validation of Noninvasive Blood Pressure Device
This is a prospective, nonrandomized multi-center study for the investigation of noninvasive sphygmomanometers. The purpose of the study is to validate the clinical performance of the Masimo noninvasive blood pressure device…
- Conditions
- Healthy, Hypertension, Hypotension
- Trial name
- NCT04676152
- Testing
- Masimo Noninvasive Blood Pressure Device
- Where
- 2 sites in United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Masimo Corporation
Catecholamine-resistant Hypotension (CRH), Distributive Shock
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
This is a Phase 3, double-blind, randomized study of LJPC-501 (angiotensin II) in adult patients diagnosed with catecholamine-resistant hypotension (CRH) conducted in multiple centers globally.
- Conditions
- Catecholamine-resistant Hypotension (CRH), Distributive Shock, High Output Shock, Sepsis
- Trial name
- ATHOS-3 (NCT02338843)
- Testing
- LJPC-501
- Where
- 115 sites in United States, Australia and 8 more
- Volunteers
- 344 people
- Sponsor
- La Jolla Pharmaceutical Company